Table 2.

Virologic results after 48 weeks of TDF/FTC/EVG/cobi plus DRV.

	Week 24	Week 48
Proportion with HIV-1 RNA <40 copies/mL – ITT
Overall (N=21)	15/21 (71%)	14/21 (67%)
Patients with baseline HIV viremia (N=15)	11/15 (73%)	10/15 (67%)
Patients with baseline HIV-1 RNA <40copies/mL (N=6)	4/6 (67%)	4/6 (67%)
Protocol-defined virologic failure
Missing data	3 (14%)	2 (10%)
Lost to follow-up	2 (10%)	2 (10%)
Discontinued treatment for SAE/death	0	1 (5%)
Discontinued treatment for other reason	0	1 (5%)
HIV-1 RNA ≥40 copies/mL	1 (5%)	1 (5%)

Abbreviations: ITT, intention-to-treat; TDF/FTC/EVG/cobi plus DRV, tenofovir disoproxil fumarate, emtricitabine, and cobicistat-boosted elvitegravir plus darunavir; SAE, serious adverse event.